

**In the Specification**

Please amend the specification as follows:

~~On page 37, line 28, after the sequence describing ISIS-15839, please delete "SEQ ID NO:1" and insert therefor -- SEQ ID NO: 55 -- .~~

~~On page 37, line 31, after the sequence describing ISIS-13312, please delete "SEQ ID NO:48" and insert therefor -- SEQ ID NO: 56 -- .~~

~~On page 37, line 33, after the sequence describing ISIS-9605, please delete "SEQ ID NO:49" and insert therefor -- SEQ ID NO: 57 -- .~~

~~On page 37, line 34, after the sequence describing 9606, please delete "SEQ ID NO:49" and insert therefor -- SEQ ID NO: 58 -- .~~

~~On page 97, line 3, please delete "SEQ ID NO: 1" and insert therefor -- SEQ ID NO: 55 -- .~~

**In the Claims**

Please amend claims 80-83 as follows:

a<sup>1</sup>  
80. **(Amended)** The pharmaceutical composition according to claim 1, wherein said oligonucleotide is selected from the group consisting of [ISIS-2302, ISIS-15839, ISIS-1939, ISIS-2922, ISIS-

DOCKET NO.: ISIS-3510

PATENT

13312, ISIS-3521, ISIS-9605, ISIS-9606, ISIS-14859, ISIS-2503, ISIS-5132, ISIS-14803, ISIS-28089, ISIS-104838 and ISIS-2105] SEQ ID NOS: 1, 55, 2, 48, 56, 49, 57, 58, 50, 16, 19, 51, 52, 53, and 54.

81. **(Amended)** The rectal enema according to claim 31, wherein said oligonucleotide is selected from the group consisting of [ISIS-2302, ISIS-15839, ISIS-1939, ISIS-2922, ISIS-13312, ISIS-3521, ISIS-9605, ISIS-9606, ISIS-14859, ISIS-2503, ISIS-5132, ISIS-14803, ISIS-28089, ISIS-104838 and ISIS-2105] SEQ ID NOS: 1, 55, 2, 48, 56, 49, 57, 58, 50, 16, 19, 51, 52, 53, and 54.

82. **(Amended)** The rectal suppository according to claim 39, wherein said oligonucleotide is selected from the group consisting of [ISIS-2302, ISIS-15839, ISIS-1939, ISIS-2922, ISIS-13312, ISIS-3521, ISIS-9605, ISIS-9606, ISIS-14859, ISIS-2503, ISIS-5132, ISIS-14803, ISIS-28089, ISIS-104838 and ISIS-2105] SEQ ID NOS: 1, 55, 2, 48, 56, 49, 57, 58, 50, 16, 19, 51, 52, 53, and 54.

83. **(Amended)** The pharmaceutical composition according to claim 46, wherein said oligonucleotide is selected from the group consisting of [ISIS-2302, ISIS-15839, ISIS-1939, ISIS-2922, ISIS-